Entrada Therapeutics (NASDAQ:TRDA) Receives "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA - Free Report) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Entrada Therapeutics' Q2 2025 earnings at ($0.98) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($3.65) EPS, Q1 2026 earnings at ($1.13) EPS, Q2 2026 earnings at ($1.12) EPS, Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.42) EPS.

Entrada Therapeutics Stock Down 1.6%

NASDAQ:TRDA traded down $0.12 during midday trading on Tuesday, hitting $7.50. The stock had a trading volume of 103,059 shares, compared to its average volume of 130,987. Entrada Therapeutics has a one year low of $7.10 and a one year high of $21.79. The company has a market capitalization of $284.65 million, a price-to-earnings ratio of 4.72 and a beta of 0.04. The stock has a 50-day moving average of $8.64 and a 200 day moving average of $13.07.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.36. The business had revenue of $8.75 million for the quarter, compared to analysts' expectations of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. On average, sell-side analysts anticipate that Entrada Therapeutics will post 1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in Entrada Therapeutics in the fourth quarter valued at approximately $36,000. SG Americas Securities LLC increased its stake in shares of Entrada Therapeutics by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company's stock valued at $243,000 after purchasing an additional 4,291 shares in the last quarter. LPL Financial LLC increased its stake in shares of Entrada Therapeutics by 12.9% in the 4th quarter. LPL Financial LLC now owns 55,154 shares of the company's stock valued at $954,000 after purchasing an additional 6,310 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Entrada Therapeutics by 127.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 217,006 shares of the company's stock valued at $3,752,000 after purchasing an additional 121,598 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Entrada Therapeutics by 22.1% in the 4th quarter. Legal & General Group Plc now owns 19,899 shares of the company's stock valued at $344,000 after purchasing an additional 3,601 shares in the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.